Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for neurological disorders. A number of drug development programs are currently being conducted to evaluate our drug candidates in diseases such as bipolar disorder and Friedreich's ataxia.
We currently market recombinant Protein A, which partially funds the advancement of our product development pipeline while supporting our financial stability.